NCT03341520 2026-04-17
GAZAI
Heidelberg University
Phase 2 Completed
Clinical Trials
14 trialsNCT06561360 2026-04-15
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04169737 2026-04-14
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04450173 2026-04-13
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
University of California, Davis
Phase 2 Active not recruiting
NCT04560322 2026-04-13
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
Phase 2 Recruiting
NCT05798156 2026-04-08
R-Pola-Glo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT06108232 2026-04-07
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04722172 2026-04-06
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT02537613 2026-04-01
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT03824483 2026-03-27
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06192888 2026-03-27
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06793189 2026-03-24
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Recruiting